Ramos RMA, Vargas LH

Language: Spanish
References: 19
Page: 122-126
PDF size: 102.95 Kb.

ABSTRACT

BACKGROUND. Increase on failure to antiretroviral treatment in HIV patients has been seen. The detection of mutations through genotype studies brings down costs and raises the possibility of success in rescue therapy. The objective was to identify the frequency of resistance to antiretroviral treatment through genotype studies in patients with failure treatment attended at Queretaro General Hospital.
MATERIAL AND METHODS. A transversal, descriptive study was made. Patients who showed no response to treatment with the International AIDS Society-USA guidelines were identified. Patients who had not adherence, and with opportunistic illnesses were excluded. The mutations were analyzed with International AIDS Society-USA and Sanford Data Base guidelines. The statistic analysis included rates, and confidence intervals.
RESULTS. There were included 146 patients with HIV infection, among them, 50 showed treatment failure and 28 different nonadherence factors. Among 78 patients, 22 were included in genotyping study, the frequency of resistance was 26.5% [CI 95%; 15.9-35.3], 20 patients (90%) showed mutations associated with resistance to at least one antiretroviral medicine, 30 % [CI 95% 3.7-57.3] to the Reverse Transcriptase gene, 45%% [CI 95% 12.1-77.9] to ITRAN and IP, and 25 %[IC 95% 3.7-53.5] to the three groups. The most frequently found for ITRAN M4IL (55%), D67N (55%), K70R (50 %), T215F/Y (75%), M184V (55%), for ITRNN L1001 and K103N (50% respectively), and for the Protease gene the Protease was L90M (57%), I54 L/M/V (43%).
CONCLUSION. Know the prevalence of resistance in the HIV population is the first step to the patients has the best treatment.

REFERENCES

1. Organización Mundial de la Salud. “Global summary of the HIV/AIDS epidemic, December 2010. Datos estadísticos”. [acceso 21 enero 2012] Disponible en: http://www.who.int/hiv/data/en/index.html

2. Organización Mundial de la Salud. “Epidemiological fact sheet on HIV and AIDS”. México. 2008. [acceso 21 enero 2012] Disponible en: http://www.unaids.org

3. Aberg JA. Gallant JE. Anderson J. Oleske JM. Libman H. Currier JS et al. “Primary care guidelines for the manegment of persons infected with human inmunodeficiency virus: recomendations of the HIV Medicine Association of the Infectus Diseases Society of America”. Clin. Infect. Dis. 2004; 39(5):609-29.

4. Pujades-Rodríguez M, Balkan S, Line A, Brinkhof M, Calmy A. “Treatment failure and mortality Factors in patients receiving second-Line HIV therapy in resourcelimited countries”. JAMA 2010;304(3):303-312. 5. García-Vallejo y Domínguez A. “La genotipificación y fenotipificación de la resistencia del virus de la inmunodeficiencia humana tipo 1 (VIH-1) a los fármacos antirretrovirales”. Colomb Med. 2003;34(3):143-154.

5. Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schu¨pbach J, et al. “Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure”. PLoS ONE 2007; 2(1): e173.

6. Mendoza C, Soriano V. “Resistencia del VIH a los antirretrovirales” en Manual para la atención del paciente con VIH/SIDA. Publicaciones Permanyer. Barcelona, 2005 p.197-211. Bartmeyer B, Kuecherer C, Houareau C, Werning J,

7. Keeren K. “Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the german HIV-1 seroconverter cohort”. PLoS ONE 2010;5(10): e12718.

8. Novak R, Chen L, MacArthur D, Baxter J, Huppler K, Peng G, et al. “Prevalence of antiretroviral drug resistance mutations in chronically HIV–infected, treatment naive patients: implications for routine resistance screening before initiation of antiretroviral therapy”. Clin Infect. Dis. 2005;40:468-74.

9. Avila-Rios S, García-Morales C, Garrido-Rodriguez D, Ormsby C, Hernández-Juan R, Andrade-Villanueva J, y col. “National prevalence and trends of HIV transmitted drug resitance in Mexico”. PLoS ONE 2011;6.(11): e27812.

10. Gupta S, Fransen S, Paxinos E, Stawiski E, Huang W, Petropoulos C. “Combinations of mutations in the connection domain of Human Immunodeficiency Virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance”. Antimicrob. Agents and Chemother. 2010;54 (5): 1973–1980.

11. Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, et al. “Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection”. PLoS ONE 2011;6(7): e21734

12. Garriga C, Pérez-Elías MJ, Delgado R, Ruiz L, Nájera R, Pumarola T y col. “Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavirbased treatments”. J. Med. Virol. 2007; 79: 1617–1628.

13. Shafera R, Soo-Yon R, Pillayb D, Millerc V, Sandstromd P, Schapiroa J, et al. “Protease and reverse transcriptase mutations for drug resistance surveillance”. AIDS. 2007; 21(2): 215–223.

14. Garriga, C, Pérez-Elías, MJ., Delgado, R, Ruiz, L, Nájera, R, Pumarola, T, et al. “Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir and lopinavir/ritonavir-based treatments”. J. Med. Virol. 2007; 79: 1617–1628.

15. Avila-Rıos S, Garcıa-Morales C, Garrido-Rodrıguez D, Ormsby CE, Hernandez-Juan R, y col. “National Prevalence and Trends of HIV Transmitted Drug Resistance in Mexico”. PLoS ONE.2011; 6(11): e27812.

16. Kleist M, Menz S, Stocker H, Arasteh K, Schutte C, et al. “HIV quasispecies dynamics during pro-active treatment switching: impact on multi drug resistance and Resistance Archiving in Latent Reservoirs”. PLoS ONE 2011;6(3): e18204.

17. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F. et. al. “Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)”. AIDS, 2002. 16;3:369-79.

18. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA,et al. “A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study team for the Terry Beirn Community Programs for Clinical Research on AIDS”. AIDS, 2000. 14;9:F83-93.

19. Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, et al. “Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India”. Indian J Med Microbiol. 2009;27:231-6.